The huge global burden of malaria is repeatedly stated, to the point of triteness, yet the depressing fact remains that each year, world-wide, half-a-billion acute malaria episodes occur, and up to 3 million people – mainly African children – die in consequence.\(^1\) There is currently some renewed interest in the possibility of substantially improved control of malaria in some regions. The primary reason for this has been the widespread introduction of more effective malaria treatment, i.e. artemisinin-based combination therapy (ACT).\(^2\) Improved primary care level diagnosis through the use of rapid malaria tests is another recent development. Vector control, including use of insecticide-impregnated bed-nets, has much added potential. The inevitable emergence of antimalarial and insecticide resistance has to temper any overconfidence, however. Another, more long-term, hope for malaria control has been sparked by the recent moderate successes of the RTS,S/AS02 malaria vaccine trials.\(^3,4\) Briefly, these phase 2 studies showed short-term efficacy against malaria infection in children of around 40% in Mozambique,\(^5\) 65% in Tanzania,\(^6\) and 53% in Kenya and Tanzania.\(^7\) While immunisation may ultimately rescue mankind from malaria, or at least reduce the extent of its effects, the road towards an effective vaccine being available and used on a large scale will, in the words of commentators in the Lancet, be ‘long and chaotic’.\(^8\) With these developments in mind, a brief look at the recent South African experience with malaria as a public health problem will be instructive.

Historically, malaria control in South Africa has relied mainly on indoor residual insecticide spraying (IRS) of houses, which utilises the feeding and resting behaviour of vectors, and relies on the assumption that the vectors bite humans indoors and then rest on the walls. This is true of the two major African vectors, *Anopheles gambiae* and *A. funestus*. However, *A. arabiensis*, which is the more important vector in southern Africa with its wider range of behaviours, can be controlled but not eliminated by residual spraying of houses. IRS is labour-intensive and expensive, and requires a strong vertical programme to maintain efficacy. It has been highly successful in South Africa\(^9\) but has not been sustainable on a wide scale elsewhere in Africa. *A. arabiensis* breeds in small, sunlit temporary pools, such as cattle hoofprints, and is not amenable to larval control, unlike *A. funestus*, which prefers more permanent water.\(^9\) This latter vector, which is highly susceptible to IRS, was eliminated from the malaria transmission area in KwaZulu-Natal many years ago. In 1996, bowing to environmentalist pressure, the South African malaria control programme replaced DDT with synthetic pyrethroid insecticides. The incidence of malaria in the area rapidly increased by 500% to around 60 000 cases per year (Fig 1); a contributing factor was widespread resistance of the parasite to sulphadoxine-pyrimethamine (SP) (Fansidar), which had been used as first-line treatment for the previous decade.\(^7\) In 1999, pyrethroid-resistant *A. funestus* was found resting indoors in sprayed houses: an invasion from neighbouring Mozambique.\(^7\) A change in first-line treatment from SP to artemether-lumefantrine (Coartem) and reversion to DDT house-spraying brought the malaria incidence to historically normal levels (Fig 1), which illustrates the great importance of clinical and laboratory monitoring of antimalarial drug resistance in the parasite, and the entomological monitoring of vectors and insecticide resistance. The Lubombo Spatial Development Initiative (LSDI) Malaria Control Programme, which involves co-ordinated vector control programmes in South Africa, Swaziland and Mozambique, had a rapid and dramatic effect on reducing malaria transmission in southern Mozambique and the adjoining areas of the LSDI partners.\(^10\) One of the consequences of reduced malaria incidence is less clinical exposure of doctors to the condition.

Confidential reviews of deaths from malaria have shown that clinical assessment and treatment of malaria is frequently sub-optimal in South Africa.\(^11\) Malaria cases often present outside the traditional transmission areas, and all clinicians should be familiar with prevention, diagnosis and treatment of this dangerous disease. The introduction of rapid diagnostic (‘dipstick’) tests for malaria at primary health level has the dramatic effect on reducing malaria transmission in southern South Africa, Swaziland and Mozambique, had a rapid and instructive.\(^12\)

Compared with most of sub-Saharan Africa, South Africa is fortunate in several ways regarding malaria: it is at the southern extreme of malaria distribution on the continent, and relatively small areas experience seasonal transmission; it has a well-organised national malaria control programme; and it has a relatively well-developed scientific, economic and health infrastructure. However, problems with importation of malaria cases from neighbouring countries, antimalarial drug resistance, vector insecticide resistance, climatic events, distractions by other major public health problems such as HIV and tuberculosis, and deteriorating preventive and curative health services, provide no grounds for complacency about malaria in South Africa.

**John Frean**

National Institute for Communicable Diseases and University of the Witwatersrand, Johannesburg

**References**


**LETTER**

**Neonatal cholinergic syndrome - organophosphate poisoning or herbal medicine intoxication?**

**To the Editor:** May I commend Van Wyk and Els on their successful management of a 10-day-old baby with organophosphate poisoning? A low plasma pseudocholinesterase (butyrylcholinesterase) level as reported in the patient is a confirmation of organophosphate poisoning irrespective of the source of the poison or the mode of exposure. Perhaps ‘Organophosphate poisoning in a newborn’ would have been a more appropriate title. I would like to raise a few points relating to the potential source of poisoning and management of the patient.

A history of organophosphate exposure may not be evident in neonates presenting with cholinergic symptoms, the effects depend on the type of chemical, its concentration and length of exposure. Exposure can occur in various ways, such as inhalation or absorption through intact skin from contact with contaminated work clothes of an adult, which can explain cases where no pesticides were used in the home. Clothes may remain contaminated even after being laundered, at which stage the dose may not be toxic to adults but enough to cause symptoms in babies. Sudden onset of feeding difficulties, fever, cough, respiratory distress and lethargy, as initially presented by Van Wyk and Els’s patient, are similar to symptoms reported for early severe organophosphate poisoning, suggesting that exposure might have occurred before the baby was taken to the traditional healer.

A possible differential diagnosis not considered in this patient was cyanide poisoning. Herbal products can contain high levels of heavy metals and cyanide. It might have been useful to analyse heavy metals and cyanide, in addition to organophosphate, in the samples sent for toxicological studies.

The authors did not report the baby’s blood glucose level, and yet 5% dextrose saline was infused. Moderate to severe hyperglycaemia has been reported in patients with organophosphate poisoning, which is believed to be due to secondary release of catecholamines from the adrenal medulla and may require insulin. The relative risk of dying from hyperglycaemia has been reported to be increased when the maximum glucose level is over 150 mg/dl on admission.

Atropine has been successfully used in the treatment of children, but is not without adverse effects. Combination with an oxime may reduce atropine toxicity. Oxime is more useful early in the presentation (36 - 48 hours), and is recommended when the plasma pseudocholinesterase level is below 25% of normal and the cholinergic poison is unknown, it might have been worth a trial in this patient.

**Kazeem A Oshikoya**  
Department of Pharmacology  
Lagos State University College of Medicine, and  
Department of Paediatrics  
Lagos State University Teaching Hospital  
Ikeja, Lagos  
Nigeria


**4 SAJCH MAY 2009 VOL.3 NO.1**